This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Comparison of the Safety and Comfort of AC-170

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Aciex Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01495338
First received: December 15, 2011
Last updated: September 13, 2017
Last verified: September 2017
  Purpose
The purpose of this study is to evaluate the safety and comfort of AC-170 compared to a placebo.

Condition Intervention Phase
Normal Ocular Health Drug: AC-170 0.17% Drug: AC-170 0.24% (Formulation 1) Drug: AC-170 0.24% (Formulation 2) Drug: Olopatadine hydrochloride 0.2%/Tears Naturale II Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Aciex Therapeutics, Inc.:

Primary Outcome Measures:
  • Drop Comfort Score [ Time Frame: during 3 minute period ]
    drop comfort on 0-10 scale


Enrollment: 60
Study Start Date: December 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AC-170 0.17% Drug: AC-170 0.17%
1 drop in one eye at one timepoint
Experimental: AC-170 0.24% (Formulation 1) Drug: AC-170 0.24% (Formulation 1)
1 drop in one eye at one timepoint
Experimental: AC-170 0.24% (Formulation 2) Drug: AC-170 0.24% (Formulation 2)
1 drop in one eye at one timepoint
Placebo Comparator: Olopatadine hydrochloride 0.2%/Tears Naturale II Drug: Olopatadine hydrochloride 0.2%/Tears Naturale II
1 drop in one eye at one timepoint

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Able and willing to avoid the use of ocular medications or topical ocular preparations within protocol specific time period.

Exclusion Criteria:

  • Known contraindications or sensitivities to the study medication or its components.
  • Any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters.
  • Use of disallowed medications during the period indicated prior to the study enrollment or during the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01495338

Locations
United States, Massachusetts
Andover Eye Associates
Andover, Massachusetts, United States, 01810
Sponsors and Collaborators
Aciex Therapeutics, Inc.
  More Information

Responsible Party: Aciex Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01495338     History of Changes
Other Study ID Numbers: 11-100-0013
Study First Received: December 15, 2011
Last Updated: September 13, 2017

Additional relevant MeSH terms:
Olopatadine Hydrochloride
Cetirizine
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Anti-Allergic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 19, 2017